In Every Issue
E-Media
NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers [...]
By
What’s on your mind: Opinions
OPINIONS Information standards In the November/December issue of PharmaVOICE, we [...]
By
Raise Your Voice: Letters
LETTERS Two critical areas of success Missed Opportunities Your article [...]
By
Letter from the Editor
Funding in a closed space The healthcare private equity market [...]
By Taren Grom, Editor
E-Media
NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers [...]
NEW ELECTRONIC AND WEB-BASED APPLICATIONS, SITES, AND TECHNOLOGIES PatientLinx.com Offers [...]
By
What’s on your mind: Opinions
OPINIONS Information standards In the November/December issue of PharmaVOICE, we [...]
OPINIONS Information standards In the November/December issue of PharmaVOICE, we [...]
By
Raise Your Voice: Letters
LETTERS Two critical areas of success Missed Opportunities Your article [...]
LETTERS Two critical areas of success Missed Opportunities Your article [...]
By
Letter from the Editor
Funding in a closed space The healthcare private equity market [...]
Funding in a closed space The healthcare private equity market [...]
By
Taren Grom, Editor
On The Cover
Venture Capital: Funding Challenges
VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded. IN THE VAULT … KEN ANDERSEN. [...]
VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded. IN THE VAULT … KEN ANDERSEN. [...]
By
Taren Grom, Editor
Features
Dr. Donald G. Payan — Reaching for the Stars Through Molecules
As cofounder, executive VP, and chief scientific officer of Rigel Pharmaceuticals, Dr. Donald G. Payan intends to have his company become the brightest star among those hunting for new drugs. LIFE’S BIGGEST DECISIONS OFTEN CAN BE ATTRIBUTED TO COINCIDENCE. In the mid-1960s, Dr. Payan arrived in California to study physics and math at Stanford University, [...]
As cofounder, executive VP, and chief scientific officer of Rigel Pharmaceuticals, Dr. Donald G. Payan intends to have his company become the brightest star among those hunting for new drugs. LIFE’S BIGGEST DECISIONS OFTEN CAN BE ATTRIBUTED TO COINCIDENCE. In the mid-1960s, Dr. Payan arrived in California to study physics and math at Stanford University, [...]
By
Taren Grom, Editor
Addressing Pharma’s $40 Billion Challenge
Michael Perry, Ph.D., president and CEO, and Arthur Reidel, chairman, of Pharsight, outline the potential solutions and describe the remaining obstacles to successful implementation of technology as a way to unclog the pipeline.
Michael Perry, Ph.D., president and CEO, and Arthur Reidel, chairman, of Pharsight, outline the potential solutions and describe the remaining obstacles to successful implementation of technology as a way to unclog the pipeline.
By
A Community Approach
As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronted with heavy regulations and intense competition, finding ways to develop [...]
As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronted with heavy regulations and intense competition, finding ways to develop [...]
By
Kim Ribbink
Delivering on the Promise
BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict that 20% of all pharmaceuticals will involve drug-delivery formulations. Frost & Sullivan estimated the [...]
BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict that 20% of all pharmaceuticals will involve drug-delivery formulations. Frost & Sullivan estimated the [...]
By
Elisabeth Pena
